We are live on ! Find out more
LENZ

LENZ Therapeutics
LENZ

94 hedge funds and large institutions have $573M invested in LENZ Therapeutics in 2024 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 33 increasing their positions, 20 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 8

65% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 20

29% more capital invested

Capital invested by funds: $445M → $573M (+$128M)

21% more funds holding

Funds holding: 78 → 94 (+16)

4.1% more ownership

Funds ownership: 68.13% → 72.23% (+4.1%)

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

Holders
94
Holders Change
+16
Holders Change %
+20.51%
% of All Funds
1.24%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
24
Increased
33
Reduced
20
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
PBA
Paradigm Biocapital Advisors
New York
+$23.5M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$11.4M
3
BlackRock
BlackRock
New York
+$6.88M
4
State Street
State Street
Massachusetts
+$6.25M
5
UBS Group
UBS Group
Switzerland
+$2.43M

Top Sellers

1
EC
EcoR1 Capital
California
-$8.23M
2
SB
Samsara BioCapital
California
-$6.75M
3
PHP
Parkman Healthcare Partners
Connecticut
-$3.31M
4
SSA
Schonfeld Strategic Advisors
New York
-$2.55M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
-$2.47M
Name Holding Trade Value Shares
Change 		Change in
Stake
RCM
1
RA Capital Management
Massachusetts
$121M – – –
AWG
2
Alpha Wave Global
New York
$104M – – –
Vanguard Group
3
Vanguard Group
Pennsylvania
$34M +$1.82M +59,630 +5%
BlackRock
4
BlackRock
New York
$33.4M +$6.88M +225,604 +24%
7IH
5
72 Investment Holdings
Connecticut
$29.4M – – –
SB
6
Samsara BioCapital
California
$28.5M -$6.75M -221,492 -18%
SAM
7
Sectoral Asset Management
Quebec, Canada
$28.2M – – –
RI
8
RTW Investments
New York
$24.9M – – –
T. Rowe Price Associates
9
T. Rowe Price Associates
Maryland
$23.8M +$11.4M +374,326 +83%
Point72 Asset Management
10
Point72 Asset Management
Connecticut
$22.6M -$2.47M -81,021 -9%
PBA
11
Paradigm Biocapital Advisors
New York
$22.2M +$23.5M +770,455 New
TCM
12
Tang Capital Management
California
$22.1M – – –
State Street
13
State Street
Massachusetts
$14.3M +$6.25M +205,162 +71%
Geode Capital Management
14
Geode Capital Management
Massachusetts
$9.65M -$122K -3,998 -1%
IC
15
Ikarian Capital
Texas
$4.32M -$1.68M -55,011 -27%
Alyeska Investment Group
16
Alyeska Investment Group
Illinois
$4.1M +$610K +20,000 +16%
Northern Trust
17
Northern Trust
Illinois
$4.02M +$294K +9,649 +7%
Charles Schwab
18
Charles Schwab
California
$3.67M +$117K +3,825 +3%
TD Asset Management
19
TD Asset Management
Ontario, Canada
$2.97M +$2.28M +74,690 +264%
Morgan Stanley
20
Morgan Stanley
New York
$2.66M +$1.27M +41,806 +83%
UBS Group
21
UBS Group
Switzerland
$2.48M +$2.43M +79,783 +1,298%
Wealth Enhancement Advisory Services
22
Wealth Enhancement Advisory Services
Minnesota
$2.4M +$1.07K +35 +0%
Manulife (Manufacturers Life Insurance)
23
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$1.96M +$1.12M +36,582 +117%
GIM
24
Granahan Investment Management
Massachusetts
$1.5M +$1.58M +51,842 New
Goldman Sachs
25
Goldman Sachs
New York
$1.44M +$510K +16,732 +51%
1
2 3 4 5

LENZ Hedge Fund Activity: Q4 2024 in Review

94 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in LENZ Therapeutics (LENZ) for Q4 2024, worth a combined $573M — up 29% from $445M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new LENZ positions and 8 closed out — a net gain of 16 holders — while 33 added to existing stakes and 20 trimmed.

The largest buyer was Paradigm Biocapital Advisors, opening a new position worth an estimated $23.5M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $8.23M sold.

  • 94 institutional investors held LENZ Therapeutics (LENZ) as of Q4 2024, up from 78 in Q3 2024.
  • Funds reported $573M of LENZ Therapeutics stock for Q4 2024, up 29% quarter-over-quarter.
  • 24 funds opened new LENZ Therapeutics positions in Q4 2024 and 8 closed out, a net change of +16 holders.
  • The largest LENZ Therapeutics buyer in Q4 2024 was Paradigm Biocapital Advisors, an estimated $23.5M added.
  • The largest LENZ Therapeutics seller in Q4 2024 was EcoR1 Capital, an estimated $8.23M sold.

Based on aggregated 13F filings for Q4 2024.